JP2000154143A - Hyperlipemia-ameliorating agent - Google Patents

Hyperlipemia-ameliorating agent

Info

Publication number
JP2000154143A
JP2000154143A JP11358864A JP35886499A JP2000154143A JP 2000154143 A JP2000154143 A JP 2000154143A JP 11358864 A JP11358864 A JP 11358864A JP 35886499 A JP35886499 A JP 35886499A JP 2000154143 A JP2000154143 A JP 2000154143A
Authority
JP
Japan
Prior art keywords
oligosaccharides
fiber
agent
hyperlipemia
ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11358864A
Other languages
Japanese (ja)
Inventor
Hajime Inamoto
元 稲本
Zenzo Tamura
善藏 田村
Sadao Takenobu
貞夫 武信
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RNA KENKYUSHO KK
Original Assignee
RNA KENKYUSHO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RNA KENKYUSHO KK filed Critical RNA KENKYUSHO KK
Priority to JP11358864A priority Critical patent/JP2000154143A/en
Publication of JP2000154143A publication Critical patent/JP2000154143A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To prepare a hyperlipemia-ameliorating agent not causing side effect, capable of propagating Lactobacillus bifidus, capable of lowering the values of serum potassium and serum phosphorus, capable of settling headache and shoulder stiffness and helpful for patients with renal failure or the like by including dietary microfilaments (and oligosaccharides). SOLUTION: This hyperlipemia-ameliorating agent includes (A) dietary microfilaments such as purified, finely divided cellulose including >=95 wt.% α-cellulose, having 5-50 μm maximum particle diameter, and substantially not including electrolytes, (e.g. K, Na, Mg, P or the like) and caloric ingredients such as digestible carbohydrates, or (B) the ingredient A and oligosaccharides such as fructo-oligosaccharide. The weight contents of the ingredient A and the oligosaccharides preferably are respectively 5-100 wt.% and 0-60 wt.%. both based on the weight of the agent. The agent is preferably administered before and after every meal in a quantity of 0.5-6.0 g/meal in terms of the ingredient A.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、主成分として微細
食物繊維又は微細食物繊維とオリゴ糖を含有する高カリ
ウム血症、高リン血症改善;高脂血症改善;頭痛、肩凝
改善;皮膚症改善;血中ビタミン増加;痔疾改善剤に関
する。
TECHNICAL FIELD The present invention relates to improvement of hyperkalemia and hyperphosphatemia containing fine dietary fiber or fine dietary fiber and oligosaccharide as main components; improvement of hyperlipidemia; improvement of headache and shoulder stiffness; The present invention relates to an agent for improving dermatosis; increasing blood vitamins;

【0002】[0002]

【発明が解決しようとする課題】腎不全患者、透析患
者、歯疾、入れ歯の人、消化器系の弱い人、外食の多い
人などは、食物からの繊維摂取量が少ない。
[0006] Patients with renal failure, dialysis patients, dental diseases, dentures, people with weak digestive systems, and people who eat out a lot have a low fiber intake from food.

【0003】食物繊維の摂取は、後進国で多く、先進国
で少ない。現在我国は食物繊維摂取量の最も少ない国に
なっており、食事の洋風化、軟らかいものを好むこと、
加工食品、インスタント食品の増加により、また味中心
の食事、簡便に用意できる食事の多用などにより、一般
人でも食物繊維の摂取不足になってきている。本発明
は、腎不全患者、透析患者、食事制限患者、偏食者等に
多く見られる上記疾患の原因は、食物繊維の摂取不足に
主として起因すること、または食物繊維とビフィズス菌
及び乳酸桿菌の増殖因子の不足に起因することを見い出
し、これら疾患の予防、治療等の改善を目的とする。
[0003] Dietary fiber intake is high in less developed countries and low in developed countries. At present, our country is the country with the lowest dietary fiber intake, westernized diet, preference for soft foods,
Due to the increase in processed foods and ready-to-eat foods, as well as the taste-centered meals and the frequent use of easily prepared meals, the general population has become deficient in the intake of dietary fiber. The present invention is based on the finding that the above-mentioned diseases, which are often found in patients with renal insufficiency, dialysis patients, diet-restricted patients, malformed persons, etc., are mainly caused by insufficient intake of dietary fiber, or the proliferation of dietary fiber and bifidobacteria and lactobacilli It aims to find out that it is caused by a deficiency of factors and to prevent or treat these diseases.

【0004】[0004]

【課題を解決するための手段】本発明は、主成分として
微細食物繊維又は微細食物繊維とオリゴ糖を含有する高
カリウム血症の改善、高リン血症の改善、高脂血症の改
善、頭痛、肩凝の改善・解消、痙瘡、毛嚢炎、色素沈
着、ふけ、皮膚乾燥等の皮膚疾の改善、血中ビタミンの
増加、各種痔疾の改善に用いられる医薬及び食品であ
る。
DISCLOSURE OF THE INVENTION The present invention is directed to improving hyperkalemia, improving hyperphosphatemia, improving hyperlipidemia, improving hyperlipidemia, which contains fine dietary fiber or fine dietary fiber and oligosaccharides as main components. Pharmaceuticals and foods used for improving and eliminating headache, shoulder stiffness, acne, folliculitis, pigmentation, dandruff, skin dryness and other skin diseases, increasing blood vitamins, and improving various hemorrhoids.

【0005】微細食物繊維としては、微細セルロース、
微細ヘミセルロース、微細リグニン、微細ペクチン等を
用いることができる。とくに微細セルロースは好適であ
り、天然のパルプ、リンター、バガス等の原料を鉱酸に
より加水分解し、さらに必要に応じて機械的に粉砕し、
これを水洗、乾燥することによって粉末として得られ
る。α−セルロース分として90%以上、好ましくは9
5%以上、加水分解収率が85%以上、好ましくは95
%以上、最大粒子径が200μm以下、好ましくは10
0μm以下、さらに好ましくは5〜50μmで、かつ、カ
リウム、ナトリウム、マグネシウム、リン等の電解質及
び可消化性の炭水化物等のカロリー成分を実質的に含ま
ない精製された粉末が用いられる。
[0005] As fine dietary fiber, fine cellulose,
Fine hemicellulose, fine lignin, fine pectin and the like can be used. Particularly fine cellulose is suitable, natural pulp, linters, hydrolyzing raw materials such as bagasse with mineral acid, and further mechanically pulverized if necessary,
This is washed with water and dried to obtain a powder. 90% or more as α-cellulose content, preferably 9%
5% or more, hydrolysis yield is 85% or more, preferably 95% or more.
% Or more, and the maximum particle diameter is 200 μm or less, preferably 10 μm or less.
A purified powder having a particle size of 0 μm or less, more preferably 5 to 50 μm, and substantially free of electrolytes such as potassium, sodium, magnesium and phosphorus and caloric components such as digestible carbohydrates is used.

【0006】本発明で用いるオリゴ糖としては、フラク
トオリゴ糖、ガラクトオリゴ糖等を用いることができ
る。とくにフラクトオリゴ糖は好適であり、シュークロ
ースにフラクトシルトランスフェラーゼを作用させて得
られる。その具体的な製造法は、特公昭59−5383
4号公報に記載されている。オリゴ糖は腸内のビフィズ
ス菌及び乳酸桿菌を増殖させる働きがあり、腸内細菌叢
を改善する効果が認められている。
[0006] As oligosaccharides used in the present invention, fructooligosaccharides, galacto-oligosaccharides and the like can be used. Fructooligosaccharides are particularly suitable, and are obtained by allowing fructosyltransferase to act on sucrose. The specific production method is disclosed in JP-B-59-5383.
No. 4 publication. Oligosaccharides have the function of increasing bifidobacteria and lactobacilli in the intestine, and have been found to have an effect of improving intestinal flora.

【0007】本発明においては、微細食物繊維とオリゴ
糖を配合した製剤が好ましい。両者を配合することによ
り、顆粒、細粒化のような成型体の製造が非常に簡単、
かつ、容易となる。また、オリゴ糖は良質の甘味を賦与
し、食感を改良する効果があり、水の助けを借りず、唾
液のみによる溜飲が可能となり、かつ、長期間連続して
服用することへの抵抗感も解消される。
[0007] In the present invention, a formulation containing fine dietary fiber and an oligosaccharide is preferred. By blending both, it is very easy to manufacture molded products such as granules and fine granules,
And it becomes easy. In addition, oligosaccharides impart high-quality sweetness, have the effect of improving the texture, make it possible to drink only saliva without the aid of water, and have a long-term resistance to continuous use. Is also eliminated.

【0008】微細食物繊維及びオリゴ糖の配合比率は任
意に決定できるが、製剤中に占める微細食物繊維含有量
が5%から100%の範囲にあり、かつ、オリゴ糖含有
量が0%から60%の範囲にあるものが好適である。
The mixing ratio of the fine dietary fiber and the oligosaccharide can be arbitrarily determined, but the content of the fine dietary fiber in the preparation is in the range of 5% to 100%, and the content of the oligosaccharide is 0% to 60%. % Are preferred.

【0009】本発明の製剤は摂取しやすい形に成型する
ことができ、たとえば、医薬、食品に通常用いられてい
る粉末状、顆粒状、細粒状、カプセル、錠剤に製剤する
ことができる。また、必要に応じて呈味成分、着色料、
香料、結合液等を添加することができ、かつ、コーティ
ングして製剤することもできる。
The preparation of the present invention can be formed into a form that is easy to ingest, and for example, can be prepared into powders, granules, fine granules, capsules and tablets commonly used in medicines and foods. Also, if necessary, taste components, coloring agents,
Fragrances, binding liquids, and the like can be added, and can also be coated and formulated.

【0010】本発明の製剤の服用量は、摂取食事内容に
よるが、通常微細食物繊維換算で、毎食事前後に0.5
〜6.0g/食を服用する。
The dosage of the preparation of the present invention depends on the content of the diet to be ingested, and is usually 0.5 times before and after each meal in terms of fine dietary fiber.
Take ~ 6.0 g / meal.

【0011】[0011]

【発明の効果】本発明の製剤の服用により、次の疾患が
改善される。 1.血清カリウム値が低下する。血清リン値が低下す
る。 2.高脂血症が改善され、血清脂質が低下する。 3.頭痛、肩凝が解消される。 4.座瘡、毛嚢炎、じんま疹が解消又は改善される。色
素沈着が解消又は改善される。ふけ、皮膚の乾燥が改
善、又は解消される。 5.血中のビタミン(葉酸、ビタミンB12等)が増加す
る。 6.各種痔疾が改善される。
The following diseases are improved by taking the preparation of the present invention. 1. Serum potassium levels decrease. Serum phosphorus levels decrease. 2. Hyperlipidemia is improved and serum lipids are reduced. 3. Headache and shoulder stiffness are resolved. 4. Acne, folliculitis and urticaria are eliminated or improved. Pigmentation is eliminated or improved. Dandruff, skin dryness is improved or eliminated. 5. Blood Vitamin (folic acid, vitamin B 12, etc.) is increased. 6. Various hemorrhoids are improved.

【0012】本発明の製剤は、カリウム、リン、マグネ
シウム、ナトリウム等の電解質を実質的に含まないの
で、腎不全患者、透析患者、高カリウム血症、高リン血
症、心不全などの患者でも服用できる。また、本剤はカ
ロリー成分も実質的に含まないため、毎日服用しても太
るなどの副作用がなく、服用を継続できる。
Since the preparation of the present invention does not substantially contain electrolytes such as potassium, phosphorus, magnesium, and sodium, it can be taken by patients with renal failure, dialysis patients, hyperkalemia, hyperphosphatemia, heart failure and the like. it can. In addition, since this drug does not substantially contain a caloric component, even if taken daily, there is no side effect such as weight gain and the taking can be continued.

【0013】[0013]

【実施例】実施例1 繊維剤服用と血清電解質 目 的 繊維剤の服用による、透析患者の血清電解質濃度に対す
る影響を明らかにする。 方 法 週2回6時間透析し、社会復帰している慢性透析患者1
0名に、本発明の食物繊維剤(1錠中微細食物繊維0.
189g、フラクトオリゴ糖0.082g含有、以下同
じ)を1日45錠を投与し、服用前、服用1ヶ月後およ
び2ヶ月後の血清カリウム、ナトリウム、クロール、カ
ルシウム、リン値を測定した。 結 果 表−1に示すように、血清カリウム及びリンは繊維剤の
服用により低下した。一方、ナトリウム、クロール、カ
ルシウム値に有意な変動はみられなかった。
EXAMPLES Example 1 Ingestion of Fiber Preparation and Serum Electrolyte Purpose The purpose of this study is to clarify the effect of taking a fiber preparation on serum electrolyte concentration in dialysis patients. Method Chronic dialysis patient 1 who has been rehabilitated to dialysis twice a week for 6 hours
0 dietary fiber preparations of the present invention (0.
189 g, containing 0.082 g of fructooligosaccharides, the same applies hereinafter) in a daily dose of 45 tablets, and the serum potassium, sodium, chlor, calcium, and phosphorus values were measured before administration, 1 month after administration, and 2 months after administration. Results As shown in Table 1, serum potassium and phosphorus were reduced by taking the fiber preparation. On the other hand, there was no significant change in sodium, chlor and calcium values.

【0014】[0014]

【表1】 [Table 1]

【0015】実施例2 繊維剤服用と血清脂質 目 的 繊維剤の服用による血清脂質に対する影響を明らかにす
る。 方 法 透析患者11名を、健常人1名を対象とし、1日45錠
の繊維剤を投与し、服用前と服用4ヶ月後の血清脂質値
を測定した。 結 果 表−2に示すようにして、透析患者では総コレステロー
ル、中性脂肪、リン脂質、遊離脂肪酸等が低下した。図
1及び図2に、経時的に観察した患者1例の総コレステ
ロール値とリン脂質値を示した。健常人1例のコレステ
ロール値は、同様に300mg/dlから240mg/dlに低下
した。その後180mg/dlまで低下した。
Example 2 Ingestion of Fiber Preparation and Serum Lipid Purpose The effect of taking a fiber preparation on serum lipids is clarified. Methods For 11 healthy dialysis patients, one healthy person was administered 45 tablets daily, and the serum lipid levels before and 4 months after the administration were measured. Results As shown in Table 2, total cholesterol, neutral fats, phospholipids, free fatty acids, etc. decreased in dialysis patients. 1 and 2 show the total cholesterol level and the phospholipid level of one patient observed over time. The cholesterol level of one healthy individual also dropped from 300 mg / dl to 240 mg / dl. After that, it decreased to 180 mg / dl.

【0016】[0016]

【表2】 [Table 2]

【0017】実施例3 繊維剤服用と頭痛、肩凝 目 的 繊維剤の服用による頭痛、肩凝に対する影響を明らかに
する。 方 法 慢性的又は習慣的に頭痛を有する6名及び肩凝を有する
8名(この内5名は両症状を有していた)に、繊維剤を
1日45〜15錠を投与し、両症状に対する影響をみ
た。 結 果 頭痛を有する6例中4例で頭痛は消失した。仕事ができ
ない程の強い頭痛を有する1例では、繊維剤服用を3回
断続したところ、繊維剤を服用すると頭痛は消失し、中
断するとしばらくして再発し、鎮痛剤を必要とした。肩
凝を有した8例中6例で肩凝が消失した。内2例は毎週
1〜2回マッサージを受けていたが不要となった。
Example 3 Intake of fiber preparation and headache, aim of shoulder The effects of taking a fiber preparation on headache and shoulder stiffness are clarified. METHODS: Sixteen patients with chronic or habitual headache and eight with shoulder stiffness (of which five had both symptoms) were given 45 to 15 tablets of fiber daily, We looked at the effects on the symptoms. Results Headache disappeared in 4 out of 6 cases with headache. In one case with a severe headache such that he could not work, after taking the fiber agent three times, the headache disappeared when the fiber agent was taken, and recurred after a while after discontinuation, and required an analgesic. Six of the eight patients with shoulder stiffness disappeared. Two of them received massage once or twice a week, but became unnecessary.

【0018】実施例4 繊維剤服用と皮膚症 目 的 繊維剤の服用による皮膚症に対する影響を明らかにす
る。 方 法 皮膚に異常所見を有する健常人及び透析患者計13名
に、繊維剤を1日45〜15錠を投与し、皮膚症に対す
る影響をみた。 結 果 表−3に示すように、繊維剤服用により独特の色素沈着
を示す透析患者10例中9例に著しい色素沈着の消失を
見、色白で健康色になった。服用を一時中断し、再び褐
色の色素沈着を示した患者に再び繊維剤を投与したとこ
ろ、再び消失した。毛嚢炎(座瘡を含む)は全例で消失
し、とくに2例では蛋白同化ホルモンを長期にわたって
使用し、慢性的に存在した頭部毛髪部及び項部の毛嚢炎
が消失した。またじんま疹の患者1例について、繊維剤
の服用によりじんま疹が消失した。掻痒、ふけ、皮膚乾
燥も消失した。皮膚が乾燥し“ざらざらした感”のあっ
た例では、しっとりとしてきたことが観察できた。
Example 4 Taking Fiber Preparations and Dermatosis Purpose The effects of taking fiber preparations on dermatosis are clarified. Method A total of 13 healthy persons with abnormal skin findings and 13 dialysis patients were administered 45 to 15 tablets of fibrous preparation a day to observe the effects on dermatosis. Results As shown in Table 3, remarkable disappearance of pigmentation was observed in 9 out of 10 dialysis patients who exhibited unique pigmentation by taking the fiber preparation, and the skin became fair and healthy. The patient was discontinued and the fibrous agent was administered again to the patient who showed brown pigmentation again, and disappeared again. Folliculitis (including acne) disappeared in all cases, and in particular in two cases, the use of anabolic hormones for a long period of time resulted in the disappearance of chronically present hair folliculitis in the hair and neck of the head. In addition, in one patient with urticaria, hives disappeared by taking the fiber preparation. Pruritus, dandruff and dry skin disappeared. In the case where the skin was dry and "gritty", it was observed that the skin became moist.

【0019】[0019]

【表3】 [Table 3]

【0020】実施例5 繊維剤服用と血中ビタミン 目 的 繊維剤の服用による血中ビタミン濃度に対する影響を明
らかにする。 方 法 透析患者9名に、繊維剤を1日45錠を3ヵ月間投与
し、血中葉酸及びビタミンB12を測定した。内6名では
更におよそ1ヵ月後に再検査を行った。 結 果 表−4に示すように、血中葉酸濃度は9例中6例で著し
く上昇した。ビタミンB12も2例で著しく高かった。6
例の再検査でも同様の傾向が見られた。
Example 5 Ingestion of Fiber Preparation and Blood Vitamin Purpose The effect of taking a fiber preparation on the blood vitamin concentration is clarified. METHODS dialysis patients nine, the fiber material was 3-month administration of 45 tablets per day, blood was measured folic acid and vitamin B 12. Six of them re-examined approximately one month later. Results As shown in Table 4, the blood folate concentration was significantly increased in 6 out of 9 cases. Vitamin B 12 was also significantly higher in 2 cases. 6
A re-examination of the cases showed a similar trend.

【0021】[0021]

【表4】 [Table 4]

【0022】実施例6 繊維剤服用と痔疾 目 的 繊維剤の服用による痔疾の改善効果を明らかにする。 方 法 痔出血及び脱肛のある患者4名に、繊維剤を1日45錠
を3ケ月間投与し、痔疾の改善効果を調べた。 結 果 表−5に示すように、全例で痔の出血が止まり、痔の痛
みも消失した。また脱肛の患者3例においては、脱肛し
にくくなり、かつ脱肛部を肛門内に戻して修復するのに
痛みがなく、容易に可能となった。
Example 6 Taking Fiber Preparation and Hemorrhoids Purpose The improvement effect of hemorrhoids by taking a fiber preparation is clarified. Method For 4 patients with hemorrhoidal bleeding and anal prolapse, 45 tablets per day were administered for 3 months to examine the effect of improving hemorrhoids. Results As shown in Table 5, hemorrhoid hemorrhage stopped in all cases, and the hemorrhoid pain disappeared. In three patients with anal prolapse, anal prolapse was difficult, and it was easy and easy to return the anal prolapse part back into the anus without any pain.

【0023】[0023]

【表5】 [Table 5]

【図面の簡単な説明】[Brief description of the drawings]

【図1】本発明の繊維剤を服用した透析患者の総コレス
テロール値の推移を示すグラフである。
FIG. 1 is a graph showing changes in the total cholesterol level of a dialysis patient who has taken the fiber preparation of the present invention.

【図2】本発明の繊維剤を服用した透析患者のリン脂質
の推移を示すグラフである。
FIG. 2 is a graph showing changes in phospholipids in a dialysis patient who has taken the fiber preparation of the present invention.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61P 3/00 A61P 3/00 3/06 3/06 7/00 7/00 9/14 9/14 17/00 17/00 25/06 25/06 43/00 43/00 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat ゛ (Reference) A61P 3/00 A61P 3/00 3/06 3/06 7/00 7/00 9/14 9/14 17 / 00 17/00 25/06 25/06 43/00 43/00

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 主成分として微細食物繊維又は微細食物
繊維とオリゴ糖を含有する高脂血症改善剤。
1. An agent for improving hyperlipidemia containing fine dietary fiber or fine dietary fiber and oligosaccharide as main components.
JP11358864A 1999-01-01 1999-12-17 Hyperlipemia-ameliorating agent Pending JP2000154143A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11358864A JP2000154143A (en) 1999-01-01 1999-12-17 Hyperlipemia-ameliorating agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11358864A JP2000154143A (en) 1999-01-01 1999-12-17 Hyperlipemia-ameliorating agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2320844A Division JP3055930B2 (en) 1990-11-27 1990-11-27 Hyperkalemia, hyperphosphatemia improving agent

Publications (1)

Publication Number Publication Date
JP2000154143A true JP2000154143A (en) 2000-06-06

Family

ID=18461502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11358864A Pending JP2000154143A (en) 1999-01-01 1999-12-17 Hyperlipemia-ameliorating agent

Country Status (1)

Country Link
JP (1) JP2000154143A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003339348A (en) * 2002-05-27 2003-12-02 Toyo Shinyaku:Kk Health food
WO2009116382A1 (en) * 2008-03-19 2009-09-24 森下仁丹株式会社 Inhibitor for blood phosphorus level elevation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003339348A (en) * 2002-05-27 2003-12-02 Toyo Shinyaku:Kk Health food
WO2009116382A1 (en) * 2008-03-19 2009-09-24 森下仁丹株式会社 Inhibitor for blood phosphorus level elevation
JP2011148703A (en) * 2008-03-19 2011-08-04 Morishita Jintan Co Ltd Blood phosphorus concentration elevation inhibitor
US9056122B2 (en) 2008-03-19 2015-06-16 Morishita Jintan Co., Ltd. Method for inhibition of blood phosphorus level elevation

Similar Documents

Publication Publication Date Title
US4824672A (en) Method and composition for reducing serum cholesterol
TWI359021B (en) Nutritional composition for controlling blood suga
US7067498B2 (en) Polymer controlled induced viscosity fiber system and uses thereof
US4883788A (en) Method and composition for reducing serum cholesterol
KR900007468B1 (en) Confectionery delivery system for actives
JP2002508772A (en) Health supplement
JP2005068060A (en) Pharmaceutical composition containing lactoferrin and method for producing processed food containing lactoferrin
JP3933702B2 (en) Composition for mineral supplementation after gastrectomy
JP2003533438A (en) Carbohydrate formulations for enhancing immune response (prebiotic adjuvants)
PT1588629E (en) Matrix-forming composition containing pectin
MXPA06010503A (en) Dietary supplement and method for treating digestive system-related disorders.
US5686107A (en) Chewable pharmaceutical tablets
JP2002535288A (en) Lipoprotein complexes and compositions containing them
JP3055930B2 (en) Hyperkalemia, hyperphosphatemia improving agent
WO1999017612A1 (en) Serotonin containing formulation for oral administration and method of use
CN108420890B (en) Composition with blood fat reducing effect and preparation method thereof
EP2635130B1 (en) Composition of purified soluble mannans for dietary supplements and methods of use thereof
JP2000154143A (en) Hyperlipemia-ameliorating agent
JP2000154141A (en) Dermatopathy-alleviating agent
JP2000154144A (en) In-blood vitamin-increasing agent
JP2000154142A (en) Hemorrhoid-ameliorating agent
WO2022119954A1 (en) Stable semi-solid chewable gel compositions and methods of making and using thereof
JP2000135072A (en) Shoulder stiffness relieving agent
Zillikens et al. Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis
JPH0213647B2 (en)